Scarisbrick I A, Blaber S I, Tingling J T, Rodriguez M, Blaber M, Christophi G P
Department of Physical Medicine and Rehabilitation, Mayo Medical and Graduate Schools, Rochester, MN 55905, USA.
J Neuroimmunol. 2006 Sep;178(1-2):167-76. doi: 10.1016/j.jneuroim.2006.05.022. Epub 2006 Jul 7.
The objective of this study was to define the potential scope of action of tissue kallikreins in T cell-mediated disease of the CNS. We demonstrate quantitatively the differential expression of all 15 human tissue kallikreins within brain, spinal cord and immune compartments. In human Jurkat T cells we demonstrate differential regulation of select kallikreins by CD3 receptor, Concanavilin A (Con A), interleukin 2 (IL2), and lipopolysaccharide (LPS)-mediated activation and by exposure to steroid hormones, dexamethasone, norgestrel, androstan and estradiol. The patterns of co-expression and co-regulation described point to novel effector roles for select tissue kallikreins in neurological disorders involving T cells, such as multiple sclerosis.